Mäestu, J, Lelle, R, Mäestu, E, Pind, R, Vahtra, E, Purge, P, and Mikulic, P. Long-term rowing performance development in male Olympic and World Championship medal winners compared with nonmedalists. J Strength Cond Res 37(9): e521-e526, 2023-The purpose of this study was, first, to investigate individual longitudinal 2,000 m rowing ergometer performance (2,000 erg) development of world class male rowers from the beginning of their career until reaching the elite level and to compare ELITE performance development with those who did not reach podium places and, second, to provide 2,000 erg milestones for talent prediction in rowing. Individual annual 2,000 erg performances of 54 male rowers were analyzed from age 15 and throughout their career. Olympic or World Championships medal winners (ELITE; n = 11) were compared with those who did not reach international podium places. Two thousand erg increased ( p ≤ 0.05) until the age of 24 in ELITE, while plateaued earlier for less successful rowers. No differences in the rate of performance improvement were found between ELITE and lower performers ( p > 0.05). At the age of 20, performance between ELITE and international level nonmedal winners reached significant difference (480.7 ± 20.9 W vs. 435.3 ± 33.9 W, respectively) and remained different onwards ( p ≤ 0.05). However, the average of the 10 best seasons cross-sectional performances of less successful rowers were significantly higher until age 18, compared with ELITE. ELITE rowers were able to improve their 2,000 erg performance to higher age; therefore, it is difficult to predict elite performers in junior rowers. Cross-sectional performances of less successful rowers may indicate temporary high-level performers, who might not be able to advance the elite level.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1519/JSC.0000000000004479 | DOI Listing |
Unlabelled: In recent years, there has been a growing interest in the contribution of neuroretinal degeneration to the pathogenesis of diabetic retinopathy (DR), preceding the classic vascular changes associated with DR.
Purpose: This study evaluated the impact of the polypeptide drug Retinalamin on the structural and functional condition of the retina in patients with DR using optical coherence tomography (OCT) (Topcon OCT 2000 FA, Japan) and the Diopsys Nova vision testing system for electrophysiological studies of the visual organ.
Material And Methods: The clinical study included 56 patients (112 eyes) with type 1 and type 2 diabetes and DR without macular edema.
Blood
October 2024
Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia.
Biomolecules
November 2023
Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
The bioactive sphingolipid sphingosine-1-phosphate (S1P) acts as a ligand for a family of G protein-coupled S1P receptors (S1PR1-5) to participate in a variety of signaling pathways. However, their specific roles in the neural retina remain unclear. We previously showed that S1P receptor subtype 2 (S1PR2) is expressed in murine retinas, primarily in photoreceptors and bipolar cells, and its expression is altered by retinal stress.
View Article and Find Full Text PDFBMC Nutr
October 2023
Food for Health Ireland, University College Dublin, Dublin 4, Republic of Ireland.
Background: Research on dairy consumption in China is lacking, however, some evidence has demonstrated significant changes in recent years, with a reported increase in the overall consumption of dairy products. To fully understand these changes, a systematic review was conducted to examine reported dairy intakes and differences between dairy consumption in different population groups in China.
Methods: Web of Science, Embase, and PubMed databases were searched for studies published from January 2000 to September 2022.
J Clin Pharmacol
November 2022
Merck & Co., Inc., Rahway, New Jersey, USA.
Gefapixant, a P2X3 receptor antagonist, has demonstrated efficacy in patients with refractory or unexplained chronic cough. We investigated the effect of renal impairment (RI) on the pharmacokinetics (PK) of gefapixant 50 mg in an open-label, single-dose study enrolling participants with moderate (n = 6) or severe (n = 6) RI, end-stage renal disease (ESRD; n = 6) under hemodialysis (HD) and non-HD conditions, and healthy matched controls (n = 6). Serial plasma and urine samples for gefapixant concentrations were collected at selected time points over 72 and 48 hours after dosing, respectively.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!